Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Insulin Delivery Devices Market Trends

ID: MRFR/HC/0352-CR
200 Pages
Rahul Gotadki
April 2025

Insulin Delivery Devices Market Research Report: Size, Share, Trend Analysis By Device Type (Insulin Syringes, Insulin Pens, Insulin Pumps, Smart Insulin Devices), By End Users (Hospitals, Home Care Settings, Diabetes Clinics), By Product Type (Analogue Insulin Delivery Devices, Pen-Needle Systems, Continuous Glucose Monitoring Systems), By Mode of Delivery (Subcutaneous Injection, Intravenous Injection, Inhaled Insulin) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Insulin Delivery Devices Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Market Trends

Key Emerging Trends in the Insulin Delivery Devices Market

The Insulin Delivery Devices Market is witnessing substantial growth globally, fueled by the escalating prevalence of diabetes. With an increasing number of individuals diagnosed with diabetes, there is a parallel surge in the demand for efficient and user-friendly insulin delivery devices to manage the condition effectively. The field of technology is an ever-changing one where new innovations in insulin delivery systems are hardly surprising. They form the basis of competitiveness in the market. Innovation includes pen, pump and CGM systems which are smart and can integrate with one another. These developments are designed for improving patient compliance, greater convenience to the end user before and after administration of insulin. Insulin pens is becoming the dominant avenue of getting into the market, given their improved customer acceptance. As insulin pens offer most of the ease of use; this one of the major reasons on why the population with diabetes are very fond of the approach. The market has been evolving more towards the use of valid/insulin pens instead of v/syringes because of their ease of use. One of the major concern manufacturers have is to provide best possible user interface design, such as patients-centric delivery devices. It is that which refers to the ergonomic shapes, user interactive interface and functions that will actually provide the best experience to the people with diabetes – a look that is designed with their needs and taste kept in consideration. Since the appearance of the discreet and easy-to-carry insulin pumps, continuous subcutaneous insulin infusion has become a real possibility. The subcutaneous infusion is convenient and little known to the non-medical public, being created for medical personnel. As the necessity of such appliances is rising greatly among people who want to have more freedom to frequently monitor insulin supply regardless of their busy schedule, a more active living is ensured.

Increasing emphasis is placed on patient education and training programs to enhance the proper use of insulin delivery devices. Healthcare providers are actively involved in educating patients about device features, correct usage, and self-management practices to optimize diabetes care. Growing awareness about diabetes management and the importance of timely insulin delivery is influencing market trends. Diabetes management programs, both online and offline, contribute to increased awareness, driving the adoption of advanced insulin delivery devices for better glycemic control.

Author
Author Profile
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the projected market valuation of the Insulin Delivery Devices Market by 2035?

<p>The Insulin Delivery Devices Market is projected to reach a valuation of 26.31 USD Billion by 2035.</p>

What was the market valuation of the Insulin Delivery Devices Market in 2024?

<p>In 2024, the Insulin Delivery Devices Market was valued at 15.14 USD Billion.</p>

What is the expected CAGR for the Insulin Delivery Devices Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Insulin Delivery Devices Market during the forecast period 2025 - 2035 is 5.15%.</p>

Which company is a key player in the Insulin Delivery Devices Market?

<p>Medtronic, Abbott, and Novo Nordisk are among the key players in the Insulin Delivery Devices Market.</p>

What are the projected revenues for Insulin Pumps by 2035?

<p>The projected revenues for Insulin Pumps are expected to reach between 4.0 and 7.0 USD Billion by 2035.</p>

How much is the Home Care Settings segment expected to generate by 2035?

<p>The Home Care Settings segment is projected to generate between 7.0 and 12.0 USD Billion by 2035.</p>

What is the anticipated revenue for Smart Insulin Devices by 2035?

<p>Smart Insulin Devices are anticipated to generate revenues between 3.14 and 5.31 USD Billion by 2035.</p>

What is the expected revenue range for Continuous Glucose Monitoring Systems by 2035?

<p>Continuous Glucose Monitoring Systems are expected to generate between 4.14 and 8.31 USD Billion by 2035.</p>

What revenue is projected for the Intravenous Injection mode of delivery by 2035?

<p>The Intravenous Injection mode of delivery is projected to generate between 4.0 and 6.0 USD Billion by 2035.</p>

What is the expected revenue for Pen-Needle Systems by 2035?

<p>Pen-Needle Systems are expected to generate revenues between 6.0 and 10.0 USD Billion by 2035.</p>

Market Summary

As per Market Research Future analysis, the Insulin Delivery Devices Market was estimated at 15.14 USD Billion in 2024. The insulin delivery devices industry is projected to grow from 15.92 USD Billion in 2025 to 26.31 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.1% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Insulin Delivery Devices Market is experiencing a transformative shift towards advanced technology and personalized care solutions.

  • The integration of smart technology is revolutionizing insulin delivery, enhancing patient monitoring and management. Personalized treatment approaches are gaining traction, allowing for tailored insulin regimens based on individual patient needs. Wearable devices are emerging as a significant trend, providing convenience and real-time data for diabetes management. The rising prevalence of diabetes and technological advancements in delivery systems are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 15.14 (USD Billion)
2035 Market Size 26.31 (USD Billion)
CAGR (2025 - 2035) 5.15%
Largest Regional Market Share in 2024 North America

Major Players

<a href="https://www.medtronic.com/en-us/healthcare-professionals/products.html">Medtronic </a>(US), Abbott (US), Roche (CH), Insulet (US), Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Ypsomed (CH), <a href="https://www.tandemdiabetes.com/">Tandem Diabetes Care</a> (US)

Market Trends

The Insulin Delivery Devices Market is currently experiencing a transformative phase, driven by advancements in technology and an increasing prevalence of diabetes worldwide. The integration of smart technology into insulin delivery systems appears to enhance patient adherence and improve overall management of diabetes. Moreover, the growing awareness of digital diabetes management options among patients and healthcare providers suggests a shift towards more personalized treatment approaches. This trend may lead to a greater demand for innovative devices that offer convenience and efficiency, thereby reshaping the landscape of diabetes care. In addition, the Insulin Delivery Devices Market seems to be influenced by regulatory changes and the introduction of new products that cater to diverse patient needs. The emergence of wearable devices and automated insulin delivery systems indicates a potential shift towards more user-friendly solutions. As patients seek greater control over their health, the market is likely to witness a surge in demand for devices that not only deliver insulin but also provide real-time data and insights. This evolution in the market landscape underscores the importance of continuous innovation and adaptation to meet the dynamic needs of individuals living with diabetes.

Integration of Smart Technology

The incorporation of smart technology into insulin delivery devices is becoming increasingly prevalent. These devices often feature connectivity options that allow users to monitor their insulin levels and receive alerts, thereby enhancing the management of diabetes.

Personalized Treatment Approaches

There is a noticeable shift towards personalized treatment strategies in the Insulin Delivery Devices Market. Patients are increasingly seeking devices that cater to their specific needs, which may lead to the development of customized solutions.

Emergence of Wearable Devices for Diabetes

Wearable insulin delivery devices are gaining traction, offering users convenience and ease of use. These innovations may provide real-time data and insights, potentially transforming how individuals manage their diabetes.

Insulin Delivery Devices Market Market Drivers

Rising Prevalence of Diabetes

The increasing incidence of diabetes worldwide is a primary driver for the Insulin Delivery Devices Market. According to recent statistics, the number of individuals diagnosed with diabetes is projected to reach approximately 700 million by 2045. This surge in diabetes cases necessitates effective management solutions, thereby propelling the demand for insulin delivery devices. As patients seek more efficient and user-friendly options, manufacturers are innovating to meet these needs. The growing awareness of diabetes management and the importance of insulin therapy further contribute to the expansion of the market. Consequently, the rising prevalence of diabetes is likely to continue influencing the Insulin Delivery Devices Market significantly.

Increased Investment in Diabetes Research

The surge in investment for diabetes research and development is a critical driver for the Insulin Delivery Devices Market. Governments and private organizations are allocating substantial funds to develop innovative solutions for diabetes management. This financial support is fostering advancements in insulin delivery technologies, leading to the introduction of more effective and efficient devices. Furthermore, collaborations between research institutions and manufacturers are becoming more common, facilitating the rapid translation of research findings into market-ready products. As a result, the influx of investment in diabetes research is likely to enhance the growth trajectory of the Insulin Delivery Devices Market.

Growing Demand for Home Healthcare Solutions

The shift towards home healthcare solutions is a notable trend impacting the Insulin Delivery Devices Market. Patients are increasingly opting for at-home management of their diabetes, driven by the desire for convenience and autonomy. This trend has led to a rise in the demand for portable and user-friendly insulin delivery devices that can be used outside clinical settings. Market data suggests that the home healthcare segment is expected to grow significantly, with a projected CAGR of over 10% in the coming years. This growth is indicative of a broader movement towards personalized healthcare, where patients prefer managing their conditions in the comfort of their homes, thereby influencing the Insulin Delivery Devices Market.

Technological Advancements in Delivery Systems

Technological innovations are transforming the Insulin Delivery Devices Market, enhancing the efficacy and convenience of insulin administration. Recent advancements include the development of smart insulin pens, continuous glucose monitors, and automated insulin delivery systems. These devices not only improve patient adherence but also provide real-time data for better glucose management. The integration of mobile applications with insulin delivery devices allows for personalized treatment plans, which is increasingly appealing to patients. As technology continues to evolve, the market is expected to witness a surge in demand for these advanced delivery systems, indicating a promising future for the Insulin Delivery Devices Market.

Rising Awareness and Education on Diabetes Management

The increasing awareness and education surrounding diabetes management are pivotal in shaping the Insulin Delivery Devices Market. Educational initiatives aimed at both healthcare professionals and patients are promoting better understanding of diabetes and the importance of insulin therapy. As awareness grows, patients are more likely to seek out effective insulin delivery solutions, driving market demand. Additionally, healthcare providers are emphasizing the need for proper diabetes management, which includes the use of advanced insulin delivery devices. This heightened focus on education and awareness is expected to contribute positively to the growth of the Insulin Delivery Devices Market.

Market Segment Insights

By Device Type: Insulin Pens (Largest) vs. Insulin Pumps (Fastest-Growing)

The Insulin Delivery Devices Market showcases a distribution where Insulin Pens dominate with the largest market share, attributed to their convenience and widespread adoption among patients. Insulin Syringes maintain a steady presence, primarily utilized in traditional settings, while Smart Insulin Devices, though currently smaller, are gaining traction. Insulin Pumps, once considered niche, have evolved significantly, appealing to more patients with advanced features and personalized delivery.

Insulin Pens (Dominant) vs. Insulin Pumps (Emerging)

Insulin Pens have established themselves as the dominant choice in diabetes management due to their ease of use, accuracy, and portability. These devices cater to a vast demographic, from newly diagnosed patients to long-term users, thanks to their user-friendly design and less intrusive nature. In contrast, Insulin Pumps are emerging as a transformative option for diabetic care, offering continuous insulin delivery and advanced monitoring capabilities. As technology evolves, these pumps are becoming more accessible and appealing, especially among tech-savvy patients looking for customizable treatment options. Both segments play crucial roles, meeting different patient needs and driving innovation in the market.

By End User: Hospitals (Largest) vs. Home Care Settings (Fastest-Growing)

In the Insulin Delivery Devices Market, the end-user segment is primarily driven by hospitals, which hold the largest share due to their extensive usage of insulin delivery systems in managing patient care. Hospitals benefit from having immediate access to healthcare professionals and advanced technologies, facilitating effective diabetes management. In contrast, home care settings are becoming increasingly popular, carving out a significant market share as more individuals opt for self-management of diabetes in the comfort of their homes. This shift is spurred by the increasing prevalence of diabetes and the convenience of at-home care solutions.

Hospitals (Dominant) vs. Home Care Settings (Emerging)

Hospitals hold a dominant position in the insulin delivery devices market as they are fundamental in providing acute and chronic diabetes management for patients. These facilities utilize advanced insulin delivery systems, including insulin pumps and pens, which are critical for managing high blood sugar levels in a timely manner. In comparison, home care settings are emerging as a significant segment due to rising patient autonomy, where individuals increasingly prefer to manage their diabetes at home with user-friendly devices. This transition is driven by technological advancements that enhance ease of use, coupled with the demand for personalized healthcare solutions. The growing awareness and education regarding diabetes management also fuel the adoption of insulin delivery devices in home care environments.

By Product Type: Analogue Insulin Delivery Devices (Largest) vs. pen-Needle Systems (Fastest-Growing)

<p>Within the insulin delivery devices market, Analogue Insulin Delivery Devices hold the largest market share, appealing to a broad user base seeking more precise and effective diabetes management. This segment has gained traction due to the rise in Type 1 and Type 2 diabetes cases, as well as advances in insulin formulation technology. On the other hand, Pen-Needle Systems, while smaller in market share, are rapidly expanding as they offer increased convenience and reduced pain for patients, which has led to greater adoption and market interest. The continuous evolution of technology in insulin delivery methods has seen Continuous Glucose Monitoring Systems gain momentum, working in conjunction with traditional devices to enhance patient experience. The surge in telemedicine and remote patient monitoring also aids growth, driving innovations in these devices. Factors contributing to the growth include an escalating awareness of diabetes management and lifestyle-related changes that encourage proactive health measures, which will continue to shape market trajectories for the foreseeable future.</p>

<p>Analogue Insulin Delivery Devices (Dominant) vs. Continuous Glucose Monitoring Systems (Emerging)</p>

<p>Analogue Insulin Delivery Devices remain dominant in the insulin delivery devices market due to their established reputation for efficacy and reliability in managing diabetes. These devices deliver insulin via syringes or pens, which many patients prefer for their familiarity and perceived ease of use. The technological innovations that have accompanied analogue insulins, such as pre-filled pens and improved safety features, contribute to their continued popularity. Conversely, Continuous Glucose Monitoring Systems, while considered emerging, are quickly gaining attention as they provide real-time blood glucose monitoring, enhancing diabetes management strategies. These systems represent a shift towards more integrated healthcare that aligns with the growing trend of personalized medicine, making them attractive to both patients and healthcare providers.</p>

By Mode of Delivery: Subcutaneous Injection (Largest) vs. Inhaled Insulin (Fastest-Growing)

The Insulin Delivery Devices Market showcases a distinct market share distribution among various modes of delivery, with subcutaneous injection leading the sector. This method remains a preferred choice among patients due to its ease of use and effectiveness in managing diabetes. Conversely, inhaled insulin is gaining traction, particularly among younger patients seeking a more convenient alternative. The intravenous injection, while essential in clinical settings, occupies a smaller market share as it is typically reserved for inpatient care. As the market evolves, growth trends indicate a substantial shift towards inhaled insulin as a viable option for users. Rising health awareness, coupled with advancements in technology, is driving the development of more user-friendly devices. Moreover, the convenience factor associated with inhaled insulin is likely to attract new patients, positioning it as a promising segment in the coming years.

Subcutaneous Injection (Dominant) vs. Inhaled Insulin (Emerging)

Subcutaneous injection remains the dominant mode of delivery in the Insulin Delivery Devices Market, largely due to its longstanding familiarity and reliability among diabetes patients. This method is widely recognized for its ability to provide stable insulin levels with minimal discomfort, making it a staple in diabetes management. In contrast, inhaled insulin stands out as an emerging option, appealing to a demographic that prioritizes convenience and ease of use. Patients often prefer inhaled insulin to avoid needles, and innovation in this area is making this delivery method increasingly accessible. As both segments continue to develop, the dynamics between subcutaneous injections and inhaled insulin will shape future market trends and patient preferences.

Get more detailed insights about Insulin Delivery Devices Market Research Report-Forecast to 2035

Regional Insights

The Global Insulin Delivery Devices Market has shown substantial valuations across various regions, reflecting diverse market dynamics. In 2024, the North American region is expected to hold a significant market share valued at 6.0 USD Billion, and it is projected to rise to 10.5 USD Billion by 2035, primarily driven by advanced healthcare infrastructure and increased prevalence of diabetes. Europe follows closely with a valuation of 4.5 USD Billion in 2024, expanding to 7.5 USD Billion in 2035, fueled by growing awareness and adoption of insulin delivery technologies.

The APAC region's market value is 2.5 USD Billion in 2024, anticipated to reach 4.5 USD Billion by 2035, as regional healthcare improvements and rising disposable incomes enhance access to diabetes management solutions. In South America, the market is set at 0.9 USD Billion in 2024 and is estimated to grow to 1.5 USD Billion by 2035, reflecting a gradual increase in healthcare investment. 

Meanwhile, the MEA region, valued at 0.5 USD Billion in 2024, is expected to double to 1.0 USD Billion by 2035, indicating a slow yet steady growth as healthcare infrastructures develop.Each region presents unique growth drivers, challenges, and opportunities, contributing to the overall Global Insulin Delivery Devices Market statistics as it adapts to the increasing global health needs associated with diabetes management.

Key Players and Competitive Insights

The Global Insulin Delivery Devices Market is characterized by a rapidly evolving landscape driven by technological advancements, increasing prevalence of diabetes, and rising awareness about diabetes management. Companies operating in this market are engaged in intense competition, focused on innovation and differentiation to capture market share. The overall aim is to enhance patient compliance, improve glycemic control, and ensure ease of use for consumers. The market harbors several key players, each contributing distinct features to its products while addressing the growing demands for efficiency, performance, and personalized healthcare solutions.  The competitive environment also emphasizes strategic partnerships, collaborations, and acquisitions among major firms to bolster their positions and expand their product portfolios.Insulet has established a substantial foothold in the Global Insulin Delivery Devices Market, primarily recognized for its innovative Omnipod system, which offers a tubeless insulin delivery solution. This unique approach simplifies the process of insulin administration, contributing to improved patient adherence and satisfaction.  The company's strengths lie in its advanced technology, commitment to research and development, and focus on user-centric design. Insulet has successfully leveraged partnerships with healthcare providers to enhance the accessibility of its devices, thereby increasing its market share. The strong brand loyalty and positive patient feedback further solidify Insulet's competitive position within the global landscape, enabling it to stand out among other insulin delivery device manufacturers.Roche, a significant player in the Global Insulin Delivery Devices Market, is well-known for its innovative diabetes management solutions, including insulin delivery devices integrated with extensive monitoring systems.  Roche's strengths are exemplified through its focus on comprehensive diabetes care that resonates with healthcare professionals and patients alike. The company offers a range of insulin delivery systems, such as pens and pumps, paired with precise monitoring solutions that facilitate better glycemic control. Roche has a broad market presence bolstered by strategic mergers and acquisitions that have enabled it to expand its product offerings and enhance its technological capabilities. This commitment to innovation has allowed Roche to maintain a competitive edge, ensuring that it can cater to the diverse needs of diabetes patients while fostering long-term relationships within the healthcare ecosystem.

Key Companies in the Insulin Delivery Devices Market include

Industry Developments

The Global Insulin Delivery Devices Market has seen significant developments recently, driven by innovations in technology and a growing demand for diabetes management solutions. In October 2023, Insulet Corporation announced the launch of its new Omnipod 5 insulin delivery system, designed to streamline insulin delivery for patients with Type 1 diabetes. Roche has also made strides with the expansion of its Accu-Chek product line, enhancing connectivity with digital health apps. 

Novo Nordisk reported an increase in market valuation as their new insulin formulations gained market traction, positively impacting their overall financial performance. From a mergers and acquisitions perspective, Johnson and Johnson announced plans in September 2023 to acquire a technology firm specializing in digital therapy solutions, aiming to enhance diabetes care delivery.

Additionally, Eli Lilly secured a partnership with Tandem Diabetes Care earlier this year to integrate their insulin delivery systems with new monitoring technologies, which is expected to enhance patient adherence. Ypsomed has experienced substantial growth driven by rising demand in the Asia-Pacific region, contributing to the robust development in the global landscape. Overall, advancements in automation and connectivity in insulin delivery devices are transforming diabetes management worldwide.

Future Outlook

Insulin Delivery Devices Market Future Outlook

The Insulin Delivery Devices Market is projected to grow at a 5.15% CAGR from 2025 to 2035, driven by technological advancements, increasing diabetes prevalence, and rising patient awareness.

New opportunities lie in:

  • <p>Development of smart insulin pens with integrated digital health features. Expansion of automated insulin delivery systems for improved patient compliance. Partnerships with <a href="https://www.marketresearchfuture.com/reports/telehealth-market-900">telehealth</a> platforms for remote monitoring and support services.</p>

By 2035, the market is expected to be robust, driven by innovation and increased accessibility.

Market Segmentation

Insulin Delivery Devices Market End User Outlook

  • Hospitals
  • Home Care Settings
  • Diabetes Clinics

Insulin Delivery Devices Market Device Type Outlook

  • Insulin Syringes
  • Insulin Pens
  • Insulin Pumps
  • Smart Insulin Devices

Insulin Delivery Devices Market Product Type Outlook

  • Analogue Insulin Delivery Devices
  • Pen-Needle Systems
  • Continuous Glucose Monitoring Systems

Insulin Delivery Devices Market Mode of Delivery Outlook

  • Subcutaneous Injection
  • Intravenous Injection
  • Inhaled Insulin

Report Scope

MARKET SIZE 2024 15.14(USD Billion)
MARKET SIZE 2025 15.92(USD Billion)
MARKET SIZE 2035 26.31(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.15% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Medtronic (US), Abbott (US), Roche (CH), Insulet (US), Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Ypsomed (CH), Tandem Diabetes Care (US)
Segments Covered Device Type, End Users, Product Type, Mode of Delivery, Regional
Key Market Opportunities Integration of smart technology in Insulin Delivery Devices Market enhances patient adherence and management.
Key Market Dynamics Technological advancements and regulatory changes drive innovation and competition in the insulin delivery devices market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Insulin Delivery Devices Market by 2035?

<p>The Insulin Delivery Devices Market is projected to reach a valuation of 26.31 USD Billion by 2035.</p>

What was the market valuation of the Insulin Delivery Devices Market in 2024?

<p>In 2024, the Insulin Delivery Devices Market was valued at 15.14 USD Billion.</p>

What is the expected CAGR for the Insulin Delivery Devices Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Insulin Delivery Devices Market during the forecast period 2025 - 2035 is 5.15%.</p>

Which company is a key player in the Insulin Delivery Devices Market?

<p>Medtronic, Abbott, and Novo Nordisk are among the key players in the Insulin Delivery Devices Market.</p>

What are the projected revenues for Insulin Pumps by 2035?

<p>The projected revenues for Insulin Pumps are expected to reach between 4.0 and 7.0 USD Billion by 2035.</p>

How much is the Home Care Settings segment expected to generate by 2035?

<p>The Home Care Settings segment is projected to generate between 7.0 and 12.0 USD Billion by 2035.</p>

What is the anticipated revenue for Smart Insulin Devices by 2035?

<p>Smart Insulin Devices are anticipated to generate revenues between 3.14 and 5.31 USD Billion by 2035.</p>

What is the expected revenue range for Continuous Glucose Monitoring Systems by 2035?

<p>Continuous Glucose Monitoring Systems are expected to generate between 4.14 and 8.31 USD Billion by 2035.</p>

What revenue is projected for the Intravenous Injection mode of delivery by 2035?

<p>The Intravenous Injection mode of delivery is projected to generate between 4.0 and 6.0 USD Billion by 2035.</p>

What is the expected revenue for Pen-Needle Systems by 2035?

<p>Pen-Needle Systems are expected to generate revenues between 6.0 and 10.0 USD Billion by 2035.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Device Type (USD Billion)
    2. | | 4.1.1 Insulin Syringes
    3. | | 4.1.2 Insulin Pens
    4. | | 4.1.3 Insulin Pumps
    5. | | 4.1.4 Smart Insulin Devices
    6. | 4.2 Healthcare, BY End User (USD Billion)
    7. | | 4.2.1 Hospitals
    8. | | 4.2.2 Home Care Settings
    9. | | 4.2.3 Diabetes Clinics
    10. | 4.3 Healthcare, BY Product Type (USD Billion)
    11. | | 4.3.1 Analogue Insulin Delivery Devices
    12. | | 4.3.2 Pen-Needle Systems
    13. | | 4.3.3 Continuous Glucose Monitoring Systems
    14. | 4.4 Healthcare, BY Mode of Delivery (USD Billion)
    15. | | 4.4.1 Subcutaneous Injection
    16. | | 4.4.2 Intravenous Injection
    17. | | 4.4.3 Inhaled Insulin
    18. | 4.5 Healthcare, BY Region (USD Billion)
    19. | | 4.5.1 North America
    20. | | | 4.5.1.1 US
    21. | | | 4.5.1.2 Canada
    22. | | 4.5.2 Europe
    23. | | | 4.5.2.1 Germany
    24. | | | 4.5.2.2 UK
    25. | | | 4.5.2.3 France
    26. | | | 4.5.2.4 Russia
    27. | | | 4.5.2.5 Italy
    28. | | | 4.5.2.6 Spain
    29. | | | 4.5.2.7 Rest of Europe
    30. | | 4.5.3 APAC
    31. | | | 4.5.3.1 China
    32. | | | 4.5.3.2 India
    33. | | | 4.5.3.3 Japan
    34. | | | 4.5.3.4 South Korea
    35. | | | 4.5.3.5 Malaysia
    36. | | | 4.5.3.6 Thailand
    37. | | | 4.5.3.7 Indonesia
    38. | | | 4.5.3.8 Rest of APAC
    39. | | 4.5.4 South America
    40. | | | 4.5.4.1 Brazil
    41. | | | 4.5.4.2 Mexico
    42. | | | 4.5.4.3 Argentina
    43. | | | 4.5.4.4 Rest of South America
    44. | | 4.5.5 MEA
    45. | | | 4.5.5.1 GCC Countries
    46. | | | 4.5.5.2 South Africa
    47. | | | 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Medtronic (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Abbott (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Roche (CH)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Insulet (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Novo Nordisk (DK)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Sanofi (FR)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Boehringer Ingelheim (DE)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Ypsomed (CH)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Tandem Diabetes Care (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY DEVICE TYPE
    4. | 6.4 US MARKET ANALYSIS BY END USER
    5. | 6.5 US MARKET ANALYSIS BY PRODUCT TYPE
    6. | 6.6 US MARKET ANALYSIS BY MODE OF DELIVERY
    7. | 6.7 CANADA MARKET ANALYSIS BY DEVICE TYPE
    8. | 6.8 CANADA MARKET ANALYSIS BY END USER
    9. | 6.9 CANADA MARKET ANALYSIS BY PRODUCT TYPE
    10. | 6.10 CANADA MARKET ANALYSIS BY MODE OF DELIVERY
    11. | 6.11 EUROPE MARKET ANALYSIS
    12. | 6.12 GERMANY MARKET ANALYSIS BY DEVICE TYPE
    13. | 6.13 GERMANY MARKET ANALYSIS BY END USER
    14. | 6.14 GERMANY MARKET ANALYSIS BY PRODUCT TYPE
    15. | 6.15 GERMANY MARKET ANALYSIS BY MODE OF DELIVERY
    16. | 6.16 UK MARKET ANALYSIS BY DEVICE TYPE
    17. | 6.17 UK MARKET ANALYSIS BY END USER
    18. | 6.18 UK MARKET ANALYSIS BY PRODUCT TYPE
    19. | 6.19 UK MARKET ANALYSIS BY MODE OF DELIVERY
    20. | 6.20 FRANCE MARKET ANALYSIS BY DEVICE TYPE
    21. | 6.21 FRANCE MARKET ANALYSIS BY END USER
    22. | 6.22 FRANCE MARKET ANALYSIS BY PRODUCT TYPE
    23. | 6.23 FRANCE MARKET ANALYSIS BY MODE OF DELIVERY
    24. | 6.24 RUSSIA MARKET ANALYSIS BY DEVICE TYPE
    25. | 6.25 RUSSIA MARKET ANALYSIS BY END USER
    26. | 6.26 RUSSIA MARKET ANALYSIS BY PRODUCT TYPE
    27. | 6.27 RUSSIA MARKET ANALYSIS BY MODE OF DELIVERY
    28. | 6.28 ITALY MARKET ANALYSIS BY DEVICE TYPE
    29. | 6.29 ITALY MARKET ANALYSIS BY END USER
    30. | 6.30 ITALY MARKET ANALYSIS BY PRODUCT TYPE
    31. | 6.31 ITALY MARKET ANALYSIS BY MODE OF DELIVERY
    32. | 6.32 SPAIN MARKET ANALYSIS BY DEVICE TYPE
    33. | 6.33 SPAIN MARKET ANALYSIS BY END USER
    34. | 6.34 SPAIN MARKET ANALYSIS BY PRODUCT TYPE
    35. | 6.35 SPAIN MARKET ANALYSIS BY MODE OF DELIVERY
    36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY DEVICE TYPE
    37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY END USER
    38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY PRODUCT TYPE
    39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY MODE OF DELIVERY
    40. | 6.40 APAC MARKET ANALYSIS
    41. | 6.41 CHINA MARKET ANALYSIS BY DEVICE TYPE
    42. | 6.42 CHINA MARKET ANALYSIS BY END USER
    43. | 6.43 CHINA MARKET ANALYSIS BY PRODUCT TYPE
    44. | 6.44 CHINA MARKET ANALYSIS BY MODE OF DELIVERY
    45. | 6.45 INDIA MARKET ANALYSIS BY DEVICE TYPE
    46. | 6.46 INDIA MARKET ANALYSIS BY END USER
    47. | 6.47 INDIA MARKET ANALYSIS BY PRODUCT TYPE
    48. | 6.48 INDIA MARKET ANALYSIS BY MODE OF DELIVERY
    49. | 6.49 JAPAN MARKET ANALYSIS BY DEVICE TYPE
    50. | 6.50 JAPAN MARKET ANALYSIS BY END USER
    51. | 6.51 JAPAN MARKET ANALYSIS BY PRODUCT TYPE
    52. | 6.52 JAPAN MARKET ANALYSIS BY MODE OF DELIVERY
    53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY DEVICE TYPE
    54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY END USER
    55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY PRODUCT TYPE
    56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY MODE OF DELIVERY
    57. | 6.57 MALAYSIA MARKET ANALYSIS BY DEVICE TYPE
    58. | 6.58 MALAYSIA MARKET ANALYSIS BY END USER
    59. | 6.59 MALAYSIA MARKET ANALYSIS BY PRODUCT TYPE
    60. | 6.60 MALAYSIA MARKET ANALYSIS BY MODE OF DELIVERY
    61. | 6.61 THAILAND MARKET ANALYSIS BY DEVICE TYPE
    62. | 6.62 THAILAND MARKET ANALYSIS BY END USER
    63. | 6.63 THAILAND MARKET ANALYSIS BY PRODUCT TYPE
    64. | 6.64 THAILAND MARKET ANALYSIS BY MODE OF DELIVERY
    65. | 6.65 INDONESIA MARKET ANALYSIS BY DEVICE TYPE
    66. | 6.66 INDONESIA MARKET ANALYSIS BY END USER
    67. | 6.67 INDONESIA MARKET ANALYSIS BY PRODUCT TYPE
    68. | 6.68 INDONESIA MARKET ANALYSIS BY MODE OF DELIVERY
    69. | 6.69 REST OF APAC MARKET ANALYSIS BY DEVICE TYPE
    70. | 6.70 REST OF APAC MARKET ANALYSIS BY END USER
    71. | 6.71 REST OF APAC MARKET ANALYSIS BY PRODUCT TYPE
    72. | 6.72 REST OF APAC MARKET ANALYSIS BY MODE OF DELIVERY
    73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. | 6.74 BRAZIL MARKET ANALYSIS BY DEVICE TYPE
    75. | 6.75 BRAZIL MARKET ANALYSIS BY END USER
    76. | 6.76 BRAZIL MARKET ANALYSIS BY PRODUCT TYPE
    77. | 6.77 BRAZIL MARKET ANALYSIS BY MODE OF DELIVERY
    78. | 6.78 MEXICO MARKET ANALYSIS BY DEVICE TYPE
    79. | 6.79 MEXICO MARKET ANALYSIS BY END USER
    80. | 6.80 MEXICO MARKET ANALYSIS BY PRODUCT TYPE
    81. | 6.81 MEXICO MARKET ANALYSIS BY MODE OF DELIVERY
    82. | 6.82 ARGENTINA MARKET ANALYSIS BY DEVICE TYPE
    83. | 6.83 ARGENTINA MARKET ANALYSIS BY END USER
    84. | 6.84 ARGENTINA MARKET ANALYSIS BY PRODUCT TYPE
    85. | 6.85 ARGENTINA MARKET ANALYSIS BY MODE OF DELIVERY
    86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DEVICE TYPE
    87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT TYPE
    89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODE OF DELIVERY
    90. | 6.90 MEA MARKET ANALYSIS
    91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY DEVICE TYPE
    92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY END USER
    93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT TYPE
    94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY MODE OF DELIVERY
    95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY DEVICE TYPE
    96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY END USER
    97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT TYPE
    98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY MODE OF DELIVERY
    99. | 6.99 REST OF MEA MARKET ANALYSIS BY DEVICE TYPE
    100. | 6.100 REST OF MEA MARKET ANALYSIS BY END USER
    101. | 6.101 REST OF MEA MARKET ANALYSIS BY PRODUCT TYPE
    102. | 6.102 REST OF MEA MARKET ANALYSIS BY MODE OF DELIVERY
    103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. | 6.104 RESEARCH PROCESS OF MRFR
    105. | 6.105 DRO ANALYSIS OF HEALTHCARE
    106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. | 6.109 HEALTHCARE, BY DEVICE TYPE, 2024 (% SHARE)
    110. | 6.110 HEALTHCARE, BY DEVICE TYPE, 2024 TO 2035 (USD Billion)
    111. | 6.111 HEALTHCARE, BY END USER, 2024 (% SHARE)
    112. | 6.112 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    113. | 6.113 HEALTHCARE, BY PRODUCT TYPE, 2024 (% SHARE)
    114. | 6.114 HEALTHCARE, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
    115. | 6.115 HEALTHCARE, BY MODE OF DELIVERY, 2024 (% SHARE)
    116. | 6.116 HEALTHCARE, BY MODE OF DELIVERY, 2024 TO 2035 (USD Billion)
    117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY END USER, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    7. | | 7.2.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    9. | | 7.3.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    10. | | 7.3.2 BY END USER, 2025-2035 (USD Billion)
    11. | | 7.3.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    12. | | 7.3.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    14. | | 7.4.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    15. | | 7.4.2 BY END USER, 2025-2035 (USD Billion)
    16. | | 7.4.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    17. | | 7.4.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    19. | | 7.5.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    20. | | 7.5.2 BY END USER, 2025-2035 (USD Billion)
    21. | | 7.5.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    22. | | 7.5.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.6.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    25. | | 7.6.2 BY END USER, 2025-2035 (USD Billion)
    26. | | 7.6.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    27. | | 7.6.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    29. | | 7.7.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    30. | | 7.7.2 BY END USER, 2025-2035 (USD Billion)
    31. | | 7.7.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    32. | | 7.7.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.8.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    35. | | 7.8.2 BY END USER, 2025-2035 (USD Billion)
    36. | | 7.8.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    37. | | 7.8.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    39. | | 7.9.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    40. | | 7.9.2 BY END USER, 2025-2035 (USD Billion)
    41. | | 7.9.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    42. | | 7.9.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.10.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    45. | | 7.10.2 BY END USER, 2025-2035 (USD Billion)
    46. | | 7.10.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    47. | | 7.10.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    49. | | 7.11.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    50. | | 7.11.2 BY END USER, 2025-2035 (USD Billion)
    51. | | 7.11.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    52. | | 7.11.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    54. | | 7.12.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    55. | | 7.12.2 BY END USER, 2025-2035 (USD Billion)
    56. | | 7.12.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    57. | | 7.12.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    59. | | 7.13.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    60. | | 7.13.2 BY END USER, 2025-2035 (USD Billion)
    61. | | 7.13.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    62. | | 7.13.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.14.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    65. | | 7.14.2 BY END USER, 2025-2035 (USD Billion)
    66. | | 7.14.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    67. | | 7.14.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    69. | | 7.15.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    70. | | 7.15.2 BY END USER, 2025-2035 (USD Billion)
    71. | | 7.15.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    72. | | 7.15.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    74. | | 7.16.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    75. | | 7.16.2 BY END USER, 2025-2035 (USD Billion)
    76. | | 7.16.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    77. | | 7.16.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    79. | | 7.17.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    80. | | 7.17.2 BY END USER, 2025-2035 (USD Billion)
    81. | | 7.17.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    82. | | 7.17.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.18.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    85. | | 7.18.2 BY END USER, 2025-2035 (USD Billion)
    86. | | 7.18.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    87. | | 7.18.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    89. | | 7.19.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    90. | | 7.19.2 BY END USER, 2025-2035 (USD Billion)
    91. | | 7.19.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    92. | | 7.19.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.20.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    95. | | 7.20.2 BY END USER, 2025-2035 (USD Billion)
    96. | | 7.20.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    97. | | 7.20.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    99. | | 7.21.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    100. | | 7.21.2 BY END USER, 2025-2035 (USD Billion)
    101. | | 7.21.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    102. | | 7.21.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.22.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    105. | | 7.22.2 BY END USER, 2025-2035 (USD Billion)
    106. | | 7.22.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    107. | | 7.22.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    109. | | 7.23.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    110. | | 7.23.2 BY END USER, 2025-2035 (USD Billion)
    111. | | 7.23.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    112. | | 7.23.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    114. | | 7.24.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    115. | | 7.24.2 BY END USER, 2025-2035 (USD Billion)
    116. | | 7.24.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    117. | | 7.24.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    119. | | 7.25.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    120. | | 7.25.2 BY END USER, 2025-2035 (USD Billion)
    121. | | 7.25.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    122. | | 7.25.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.26.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    125. | | 7.26.2 BY END USER, 2025-2035 (USD Billion)
    126. | | 7.26.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    127. | | 7.26.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    129. | | 7.27.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    130. | | 7.27.2 BY END USER, 2025-2035 (USD Billion)
    131. | | 7.27.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    132. | | 7.27.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    134. | | 7.28.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    135. | | 7.28.2 BY END USER, 2025-2035 (USD Billion)
    136. | | 7.28.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    137. | | 7.28.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    139. | | 7.29.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    140. | | 7.29.2 BY END USER, 2025-2035 (USD Billion)
    141. | | 7.29.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    142. | | 7.29.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    144. | | 7.30.1 BY DEVICE TYPE, 2025-2035 (USD Billion)
    145. | | 7.30.2 BY END USER, 2025-2035 (USD Billion)
    146. | | 7.30.3 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    147. | | 7.30.4 BY MODE OF DELIVERY, 2025-2035 (USD Billion)
    148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    149. | | 7.31.1
    150. | 7.32 ACQUISITION/PARTNERSHIP
    151. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Device Type (USD Billion, 2025-2035)

  • Insulin Syringes
  • Insulin Pens
  • Insulin Pumps
  • Smart Insulin Devices

Healthcare By End User (USD Billion, 2025-2035)

  • Hospitals
  • Home Care Settings
  • Diabetes Clinics

Healthcare By Product Type (USD Billion, 2025-2035)

  • Analogue Insulin Delivery Devices
  • Pen-Needle Systems
  • Continuous Glucose Monitoring Systems

Healthcare By Mode of Delivery (USD Billion, 2025-2035)

  • Subcutaneous Injection
  • Intravenous Injection
  • Inhaled Insulin
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓